We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares
FUSN

Delisted

FUSN was delisted on the 3rd of June, 2024.

Back to rankings

77 hedge funds and large institutions have $586M invested in Fusion Pharmaceuticals Inc. Common Shares in 2023 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 4

351% more capital invested

Capital invested by funds: $130M → $586M (+$456M)

244% more call options, than puts

Call options by funds: $592K | Put options by funds: $172K

113% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 8

88% more funds holding

Funds holding: 41 → 77 (+36)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
77
Holders Change
+36
Holders Change %
+87.8%
% of All Funds
1.12%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
40
Increased
17
Reduced
8
Closed
4
Calls
$592K
Puts
$172K
Net Calls
+$420K
Net Calls Change
+$420K

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$17.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.52M
3
William Blair & Company
William Blair & Company
Illinois
+$4.83M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$3.62M
5
APM
Avidity Partners Management
Texas
+$3.49M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$3.5M
2
SFM
Sphera Funds Management
Israel
-$1.31M
3
GTC
Ghost Tree Capital
New York
-$633K
4
UOC
UBS O'Connor
Illinois
-$299K
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$171K
Name Holding Trade Value Shares
Change 		Change in
Stake
Point72 Asset Management
26
Point72 Asset Management
Connecticut
$2.82M -$171K -35,257 -11%
PC
27
Pier Capital
Connecticut
$2.66M +$1.35M +277,111 New
Walleye Capital
28
Walleye Capital
New York
$2.41M +$1.22M +251,213 New
SCM
29
Sio Capital Management
New York
$2.36M – – –
UBS Group
30
UBS Group
Switzerland
$2.14M +$631K +129,783 +139%
WP
31
Woodline Partners
California
$2.14M +$702K +144,427 +185%
UOC
32
UBS O'Connor
Illinois
$2.05M -$299K -61,461 -22%
WMSA
33
Weiss Multi-Strategy Advisers
New York
$1.66M +$837K +172,357 New
SSA
34
Schonfeld Strategic Advisors
New York
$1.48M +$747K +153,792 New
BFM
35
Boothbay Fund Management
New York
$1.28M +$649K +133,550 New
ACM
36
Atika Capital Management
New York
$1.25M +$634K +130,400 New
SI
37
Sofinnova Investments
California
$1.2M +$39.8K +8,200 +7%
HP
38
HealthInvest Partners
Sweden
$1.2M +$607K +125,000 New
PFM
39
Privium Fund Management
Netherlands
$1.17M +$689K +141,750 New
Two Sigma Investments
40
Two Sigma Investments
New York
$1.14M +$578K +118,933 New
Verition Fund Management
41
Verition Fund Management
Connecticut
$1.05M +$532K +109,386 New
JF
42
Jump Financial
Illinois
$828K +$419K +86,199 New
YC
43
Yarbrough Capital
Tennessee
$739K +$374K +76,872 New
CSS
44
Cubist Systematic Strategies
Connecticut
$648K +$328K +67,460 +674,600%
SAM
45
Sectoral Asset Management
Quebec, Canada
$551K – – –
Citadel Advisors
46
Citadel Advisors
Florida
$520K +$263K +54,123 New
CIP
47
Chartwell Investment Partners
Pennsylvania
$480K +$242K +49,890 New
SCM
48
Superstring Capital Management
New York
$440K +$223K +45,801 New
Geode Capital Management
49
Geode Capital Management
Massachusetts
$378K +$41.2K +8,478 +27%
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$332K +$147K +30,315 +721%
1
2
3 4

FUSN Hedge Fund Activity: Q4 2023 in Review

77 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q4 2023, worth a combined $586M — up 351% from $130M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new FUSN positions and 4 closed out — a net gain of 36 holders — while 17 added to existing stakes and 8 trimmed.

The largest buyer was Deerfield Management, adding an estimated $17.4M. The largest seller was Artal Group, cutting an estimated $3.5M.

  • 77 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q4 2023, up from 41 in Q3 2023.
  • Funds reported $586M of Fusion Pharmaceuticals Inc. Common Shares stock for Q4 2023, up 351% quarter-over-quarter.
  • 40 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q4 2023 and 4 closed out, a net change of +36 holders.
  • The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q4 2023 was Deerfield Management, an estimated $17.4M added.
  • The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q4 2023 was Artal Group, an estimated $3.5M sold.

Based on aggregated 13F filings for Q4 2023.